Saturday, October 31, 2026

KeyCorp Stock Bearish By 28% In The Last 21 Sessions

KeyCorp Stock Bearish By 28% In The Last 21 Sessions

(VIANEWS) - Shares of KeyCorp (NYSE: KEY) fell by a staggering 28.61% in 21 sessions from $15.66 at 2023-03-10, to $11.18 at 11:16 EST on Friday, after five consecutive sessions in a row of losses. NYSE is sliding 0.87% to $14,565.28, after two successive sessions in a row of losses.

KeyCorp's last close was $11.27, 54.39% below its 52-week high of $24.71.

About KeyCorp

KeyCorp operates as the holding company for KeyBank National Association that provides various retail and commercial banking products and services in the United States. It operates in two segments, Consumer Bank and Commercial Bank. The company offers various deposits, investment products and services; and personal finance and financial wellness, student loan refinancing, mortgage and home equity, lending, credit card, treasury, business advisory, wealth management, asset management, investment, cash management, portfolio management, and trust and related services to individuals and small and medium-sized businesses. It also provides a suite of banking and capital market products, such as syndicated finance, debt and equity capital market products, commercial payments, equipment finance, commercial mortgage banking, derivatives, foreign exchange, financial advisory, and public finance, as well as commercial mortgage loans comprising consumer, energy, healthcare, industrial, public sector, real estate, and technology loans for middle market clients. In addition, the company offers community development financing, securities underwriting, brokerage, and investment banking services. KeyCorp was founded in 1849 and is headquartered in Cleveland, Ohio.

Earnings Per Share

As for profitability, KeyCorp has a trailing twelve months EPS of $1.77.

PE Ratio

KeyCorp has a trailing twelve months price to earnings ratio of 6.32. Meaning, the purchaser of the share is investing $6.32 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.38%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Feb 26, 2023, the estimated forward annual dividend rate is 0.82 and the estimated forward annual dividend yield is 4.19%.

Moving Average

KeyCorp's worth is way below its 50-day moving average of $18.36 and way below its 200-day moving average of $17.99.

Volume

Today's last reported volume for KeyCorp is 9842926 which is 54.02% below its average volume of 19091100.

Revenue Growth

Year-on-year quarterly revenue growth declined by 16.1%, now sitting on 6.74B for the twelve trailing months.

More news about KeyCorp (KEY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com